• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma

by | Sep 20, 2024 | Uncategorized

Source: CureToday articles The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant. Read More

Darzalex Regimen Boosts Rates of MRD Negativity in Newly Diagnosed, Transplant-Eligible Myeloma

by | Sep 12, 2024 | Uncategorized

Source: CureToday articles A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma. Read More

Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma

by | Sep 6, 2024 | Uncategorized

Source: CureToday articles Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. Read More

Moving Forward in Multiple Myeloma: Earlier Lines of CAR-T Cell Therapy

by | Sep 4, 2024 | Uncategorized

Source: CureToday articles Three years after the first FDA approval of CAR-T cell therapy, patients with multiple myeloma are starting to see the therapy emerge in earlier lines. Read More

Speeding Up With CAR-T Cell Therapy in Multiple Myeloma

by | Sep 3, 2024 | Uncategorized

Source: CureToday articles CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Read More

Multiple Myeloma Remission: A Glimmer of Hope

by | Aug 30, 2024 | Uncategorized

Source: CureToday articles As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope. Read More
« Older Entries
Next Entries »

Recent Content

  • FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
  • Hydroxyurea Produces Long-Term Clinical Benefits in Pediatrics With Sickle Cell Anemia
  • Crafting an Individual Treatment Plan for Patients With Prostate Cancer
  • DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy
  • NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025
  • Commitment to Patients Is Driven by a Lasting Promise
  • AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia
  • Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
  • New Options for ER+ Breast Cancer Spotlighted at Patient Event
  • Asembia’s AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT